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Objective: The purpose of this article is to describe the early clinical experience with
AWBAT.Methods:Burnpatientsrequiring(1)donorsitesor(2)treatmentofasuperﬁcial
burn wound injury were treated. A total of 45 patients with 69 distinct wounds were
included. AWBATTM-D was evaluated in donor sites and AWBATTM-S was evaluated in
superﬁcial partial-thickness burns. Days to healing, pain, hematoma/seroma formation,
and infection were noted. Ease of application, adherence, transparency, and physical
adaptability details were collected. Results: Average period to healing of donor sites
treated with AWBAT-D (n = 22 patients with n = 26 wounds) was 11.2 days, σ = 1.95,
with a range of 8–15 days and a median of 11 days. Pain rating at 24 hours was 1.2,
σ = 0.43 (n = 18) and at 48 hours mean was 1.2, σ = 0.46 (n = 15). Average period
to healing of superﬁcial burns treated with AWBAT-S (n = 15 patients with n = 18
wounds) was 8.1 days, σ = 2.48, with a range of 5–13 days and a median of 7 days.
Pain rating at 24 hours was 1.5, σ = 0.85 (n = 10) and at 48 hours mean was 1.75,
σ = 0.89 (n = 8). There was zero incidence of hematoma/seroma. No infections were
seen. Results indicate that AWBAT was easily applied with good initial adherence. It
was noted to be transparent, conformant, and pliable. Discussion: Early experience
demonstrates that AWBAT performs well on donor sites and superﬁcial partial-thickness
burns and delivers the desired attributes of a temporary skin substitute including good
adherence, infection control, transparency, adapatability, and pain control.
AWBATTM is a newly designed advanced wound care product intended to satisfy
the desired attributes of a temporary skin substitute. AWBAT consists of a thin silicone-
nylon membrane with porcine type 1 collagen peptides embedded in the nylon. AWBAT
is manufactured in such a way that the continuity of the 3-dimensional nylon structure
over the entire surface of the dressing is unharmed. AWBAT was cleared by the Food and
Drug Administration in February 2009 and is available in 3 conﬁgurations: AWBAT-D,
intended for donor sites after hemostasis has been established; AWBAT-S, intended for
clean, superﬁcial burn wounds; and AWBAT-M for use as a protective covering for meshed
autografts. AWBAT was evaluated in an early clinical experience program between May
and July 2009. Thirteen surgeons at 8 burn centers across the United States participated in
this program.
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AWBAT-D wasevaluatedfor useon donorsites,and AWBAT-S was evaluatedon clean,
superﬁcial burns.
Two conﬁgurations of AWBATTM are reported in this article. Both AWBAT-D and
AWBAT-Sconsistofathinsilicone-nylonemembranewithporcinetype1collagenpeptides
embedded in the nylon. The primary difference in the 2 conﬁgurations is the porosity.
AWBAT-D is approximately 9% porous, whereas AWBAT-S is approximately 5.5% porous.
METHODS
AWBAT-D was evaluated in patients requiring the harvest of donor sites for skin grafting of
full-thickness burns, and AWBAT-S was evaluated in patients requiring treatment of clean,
superﬁcial burns. Each group will be described in detail.
Donor sites
Following surgical preparation and draping, donor sites were harvested using a dermatome.
Depth of grafts ranged from 0.008 in to 0.015 in. Both tumescent and nontumescent tech-
niqueswereused.Onceharvested,hemostasiswasachievedusingavarietyoftechniquesin-
cluding epinephrine soaks and ﬁbrin sealants. AWBAT-D was then placed on the hemostatic
woundwiththenylon/collagen(dull)sidedownandsilicone(shiny)sideup.Anchoringone
edge, the product was smoothed over the wound to minimize wrinkling. Various anchoring
methods including steri-strips, surgical staples, sutures, and liquid adhesives were used. An
outer absorptive dressing was then placed over the secured AWBAT-D. Various products
were used including an Exu-DryTM pad or an ABD pad. The outer dressings were held in
placewithaKerlixTM rollfollowedbyanacewrap.Patientswereexaminedat24to48hours
and evaluated for hematoma/seroma formation, level of pain, and signs of infection. In ad-
dition to these clinical parameters, the product was evaluated for physical characteristics
including ease of application, adherence, and transparency. Patients were then followed
until the donor sites were healed to document the number of days it took to heal the wound.
Superﬁcial burn wounds
Superﬁcial partial-thickness burns were treated with AWBAT-S. First, blisters, loose skin,
and debris were removed from the burn wound. AWBAT-S was placed onto the wound with
the nylon/collagen (dull) side down and silicone (shiny) side up. It was gently stretched
and smoothed over the open wound to minimize wrinkling. Various anchoring methods
were used including steri-strips, surgical staples, sutures, and liquid adhesives. An outer
absorptive dressing was then placed over the secured AWBAT-S. Various products were
used including an Exu-DryTM pad or an ABD pad. The outer dressings were held in place
with a KerlixTM roll followed by an ace wrap. Patients were examined at 24 to 48 hours and
evaluated for hematoma/seroma formation, level of pain, and signs of infection. In addition
totheseclinicalparameters,theproductwasevaluatedforphysicalcharacteristicsincluding
easeofapplication,adherence,andtransparency.Patientswerethenfolloweduntilthedonor
sites were healed in order to document the number of days it took to heal the wound.
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Table 1. Summary of performance of AWBAT-D on donor sites
Days to healing
AWBAT-D Total, N Evaluable, n Range Mean Median Infection Hematoma/seroma
Patients 26 22
Wounds 34 26 8–15 11.3 ± 1.95 11.0 None None
Evaluation
Atthetimeofapplication,theproductwasevaluatedforanumberofphysicalcharacteristics
and qualities including transparency, adherence, and ease of application. In the following
days, the wounds were evaluated for hematoma or seroma formation, as well as signs
of infection. The primary end point was days to healing of the wound. Inpatients were
evaluated for healing daily. Outpatients were evaluated at routine clinic visits. All patients
were asked to evaluate their pain on a scale of 1 to 10, with 1 deﬁned as no pain and 10
deﬁned as being the worst pain ever experienced.
RESULTS
Theinitialclinicalexperienceindonorsitesandsuperﬁcialpartial-thicknessburnsconsisted
of 45 patients with a total of 69 wounds. AWBAT-D was used in 26 patients on a total of 34
wounds. AWBAT-S was used in 19 patients on a total of 35 wounds.
Donor sites
The experience using AWBAT-D for donor site wounds resulted in a total of 22 evaluable
patientswith26wounds.Datafrom4patientsarenotincludedas2patientshadtheAWBAT-
D removed at day 6 per burn center donor site protocol, 1 patient expired, and 1 patient was
lost to follow-up after surgery. Results are summarized in Table 1.
The range of days to healing was 8 to 15, the mean days to healing was 11.3 (SD
= 1.95), and median was 11.0 days. Pain was evaluated at 24 and 48 hours. At 24 hours,
the mean pain rating was 1.2 (SD = 0.43) (n = 18), and at 48 hours, the mean was
1.2 (SD = 0.46) (n = 15). No hematomas or seromas were noted. Importantly, there
were no infections reported. The physical properties of AWBAT-D were also evaluated.
Characteristics evaluated included the ease of application and the initial adherence of the
product. In the 34 wounds covered with AWBAT-D, the ease of application was excellent
(n = 27) and good (n = 7) in 100% of the patients treated. The initial adherence was
excellent (n = 17) and good (n = 17) in 100% of the patients treated. In addition, AWBAT-
Dwasconsistentlynotedtobetransparent,conformanttothewound,andpliable(seeFig1).
Superﬁcial partial-thickness burn wounds
The experience with AWBAT-S resulted in a total of 15 evaluable patients with 21 wounds.
Data from 4 patients is not included as 1 patient with excellent initial results of good
adherence of the AWBAT-S over a 24% TBSA removed all the product at day 2 while in
delirium tremens (DTs), 1 patient expired, 1 patient was lost to follow-up after surgery, and
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1 patient had AWBAT-S removed by the surgeon due to nonadherence on a deep wound.
Results are summarized in Table 2.
The range of days to healing was 5 to 13, the mean days to healing was 8.1 (SD =
2.48), and the median was 7.0 days. Pain was evaluated at 24 and 48 hours using a pain
scale of 1 to 10. At 24 hours, the mean pain rating was 1.5 (SD = 0.85) (n = 10) and at
48 hours, the mean was 1.75 (SD = 0.89) (n = 8). No hematomas or seromas were noted.
Importantly, there were no infections reported.
Table 2. Summary of AWBAT-S performance on superﬁcial partial-thickness burns
Days to healing
AWBAT-S Total, N Evaluable, n Range Mean Median Infection Hematoma/seroma
Patients 19 15
Wounds 35 21 5–13 8.1 ± 2.48 7.0 None None
Figure 1. (a) Harvested donor site, (b) postoperative day 3, AWBAT-D well adhered. Staples have
been removed. (c) Petrolatum-based product was applied to loosen AWBAT-D on day 10, and (d)
day 13 result. Used with permission from Aubrey, Inc.
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Figure 2. (a) Immediately following application of AWBAT-S to a superﬁcial partial-thickness
burn. Note ﬂuid passing through pores. (b) Product is well adhered at day 1, (C) day 3, no ﬂuid
accumulation under dressing, (D) showing signs of healing at day 8, (e) day 13, patient returned
to clinic, healed. Used with permission from Aubrey, Inc.
The physical characteristics evaluated included the ease of application and the initial
adherence of the product. Of the 35 wounds covered with AWBAT-S, the ease of application
was excellent (n = 15) or good (n = 15) on 86% of the patients treated and fair (n = 5)
in 13% of patients treated. The initial adherence was excellent (n = 9) or good (n =
26) in 100% of patients. In addition, AWBAT-S was consistently noted to be transparent,
conformant to the wound, and pliable (see Fig 2).
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Further examination of the data was done to see what impact anesthesia and tumes-
cence had on healing rates. Patients undergoing surgery for donor sites all had general
anesthesia. Approximately half of the donor sites were harvested using a tumescent
technique. The average time to healing for the tumesced group was 11.3 days whereas
the nontumesced group’s average time to healing was 11.0 day. Patients with superﬁ-
cial burns received either general anesthesia or Ketamine. The average time to heal-
ing for the general anesthesia group was 7.5 days and for the Ketamine group it was
9.3 days.
DISCUSSION
Burn injury results in the loss of integrity of the skin. The need for an ideal skin substitute
is well understood while the quest for an ideal skin substitutehas been ongoing for decades.
Since 1979, when the Food and Drug Administration cleared the ﬁrst biologically based
wound dressing (Biobrane) the search has continued. The ideal properties of a synthetic
wound dressing or biologic skin substitute have been outlined by numerous authors.1−4
The desirable properties include rapid and sustained adherence, moisture permeability, no
increase in infection, conformance to surface irregularities, transparency, physical adapt-
ability, minimization of patient discomfort, safety, and stability.
Early clinical experience data with AWBAT were collected from 8 burn centers across
the United States. The product evaluation process addressed the desired qualities of an
advanced wound care product for use in burn centers.
AWBATwasnotedtohaveexcellenttogoodinitialadherencein92.8%ofapplications.
Complicationssuchashematoma/seromaformationunderbiologicaldressingscancompli-
cate the postoperative course, leading to the need for evacuation of the ﬂuid or removal of
the dressing. Fluid collection can inhibit adherence and may also lead to infection. AWBAT
is highly porous and features nylon that provides a contiguous 3-dimensional structure. It
allows ﬂuid to pass through the pores thereby minimizing ﬂuid accumulation once placed
on the wound. Fluid passes through the AWBAT into an outer absorptive dressing as noted
in Figure 2A.
The physical characteristics of AWBAT were also evaluated. This included trans-
parency, conformance of the product to the wound, and pliability. AWBAT was consistently
noted to be transparent, conformable to the wound, and pliable.
Amongthenumerousclinicalobservationsmadeduringtheprogram,perhapsthemost
clinically signiﬁcant was the rapid healing of donor site wounds. Healing was observed in
8 to 15 days. On some wounds, particularly outpatients, it was observed that the material
could have been removed sooner because of this rapid healing process (Fig 1C). When
removing AWBAT-D from a wound that appeared to be healed, application of a petrolatum-
based product or soaking was effective. In addition, because of the rapid healing, it should
be noted that the range of days to healing might be overstated in the program statistics.
Another important clinical observation was that without exception AWBAT was used
as a primary, single application dressing. In all cases, it remained on the wound until
healing was complete. Single application dressings typically reduce the need for multiple
dressing changes and thereby the associated costs and patient discomfort. Cost data were
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not speciﬁcally tracked in this program; therefore, no speciﬁc conclusions can be drawn
regarding cost savings.
Data were collected on the patient’s perception of pain from those patients who were
able to verbalize. The data clearly indicate that patients treated with AWBAT had very low
postoperative pain scores. In addition, there were many anecdotal comments from the burn
care teams regarding the minimal level of pain in patients treated with AWBAT.
Evaluation of AWBAT is continuing in multicenter, comparative trials.
SUMMARY
AWBAT performs well as a donor site dressing and as a treatment of superﬁcial partial-
thickness burns. Early evaluation indicates that AWBAT delivers the desired attributes of an
advanced wound burn dressing, including good adherence, moisture control, transparency,
and physical adaptability. Importantly, AWBAT performed strongly in the areas of infection
control and pain management.
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